AQR Capital Management
PSTX

AQR Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

AQR Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,645
Closed -$102K – 3231
2024
Q4 		$102K Sell
10,645
-313,455
-97% -$1.64M ﹤0.01% 2761
2024
Q3 		$927K Buy
324,100
+272,359
+526% +$843K ﹤0.01% 1887
2024
Q2 		$151K Buy
51,741
+40,882
+376% +$112K ﹤0.01% 2459
2024
Q1 		$34.6K Sell
10,859
-12,781
-54% -$42.6K ﹤0.01% 2382
2023
Q4 		$79.4K Sell
23,640
-63,343
-73% -$163K ﹤0.01% 2286
2023
Q3 		$207K Sell
86,983
-61,919
-42% -$130K ﹤0.01% 2134
2023
Q2 		$262K Buy
148,902
+113,690
+323% +$290K ﹤0.01% 1990
2023
Q1 		$108K Buy
+35,212
New +$211K ﹤0.01% 2111

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AQR Capital Management's PSTX Position: Q1 2025 in Review

AQR Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 10,645 shares — an estimated $102K sold.

AQR Capital Management first reported a position in PSTX in Q1 2023 and held it in 8 quarters. The position peaked at $927K in Q3 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • AQR Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • AQR Capital Management sold 10,645 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $102K.
  • AQR Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 8 quarters.
  • AQR Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $927K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on AQR Capital Management's 13F filing for Q1 2025, filed 15 May 2025.